News
Filter
-
3 LifeArc Ventures’ portfolio companies celebrated in new report on most innovative life science businesses in UK
Read more: 3 LifeArc Ventures’ portfolio companies celebrated in new report on most innovative life science businesses in UK -
New £30m initiative to address global threat by accelerating the pace of antimicrobial innovation
Read more: New £30m initiative to address global threat by accelerating the pace of antimicrobial innovation -
LifeArc welcomes Stéphane Maikovsky as Interim CEO
Read more: LifeArc welcomes Stéphane Maikovsky as Interim CEO -
LifeArc welcomes new lead and chair to head its Childhood Cancer Translational Challenge
Read more: LifeArc welcomes new lead and chair to head its Childhood Cancer Translational Challenge -
Unveiling the future of cell and gene therapies in the UK
Read more: Unveiling the future of cell and gene therapies in the UK -
Dr Melanie Lee CBE steps down as CEO of LifeArc
Read more: Dr Melanie Lee CBE steps down as CEO of LifeArc -
LifeArc welcomes news of the UK rejoining Horizon Europe, the EU science research scheme
Read more: LifeArc welcomes news of the UK rejoining Horizon Europe, the EU science research scheme -
LifeArc and the Francis Crick Institute partner with five African research institutions to support scientists
Read more: LifeArc and the Francis Crick Institute partner with five African research institutions to support scientists -
LifeArc joins Infection Innovation Consortium to help tackle infectious diseases
Read more: LifeArc joins Infection Innovation Consortium to help tackle infectious diseases -
New Alzheimer’s treatment ‘lecanemab’ approved for use in the US
Read more: New Alzheimer’s treatment ‘lecanemab’ approved for use in the US -
LifeArc and DEBRA Austria launch £2.5m funding call for repurposing therapies for Epidermolysis Bullosa
Read more: LifeArc and DEBRA Austria launch £2.5m funding call for repurposing therapies for Epidermolysis Bullosa -
Catriona Crombie talks to Rare Revolution about LifeArc’s investment of more than £100 million into rare disease research by 2030
Read more: Catriona Crombie talks to Rare Revolution about LifeArc’s investment of more than £100 million into rare disease research by 2030